



---

---

## TEXAS STATE BOARD OF PHARMACY

---

---

1601 Congress Ave, Room 2.013  
Austin, Texas

Tuesday, May 7, 2024

### MINUTES<sup>1</sup>

### BOARD BUSINESS MEETING

#### Tuesday, May 7, 2024

President Julie Spier, R.Ph., called the meeting to order at 9:00 a.m. Other Board Members present were Vice President Donnie Lewis, R.Ph.; Treasurer Rick Fernandez, R.Ph.; Garrett Marquis; Randy Martin, Pharm.D., R.Ph.; Bradley A. Miller, Ph.T.R.; Donna Montemayor, R.Ph.; Ian Shaw; Suzette Tijerina, R.Ph.; Rick Tisch; and Jenny Downing Yoakum, R.Ph.

Staff present were Daniel Carroll, Pharm.D., R.Ph., Executive Director/Secretary; Megan Holloway, General Counsel; Caroline Hotchkiss, Director of Enforcement; John Griffith, Litigation Counsel; Ann Driscoll, Ph.T.R., Director of Operations; Ruben Leal, Budget Analyst; David Meryman, Ph.T.R., Prescription Monitoring Program Manager; Mary Martha Murphy, Deputy Litigation Counsel; Eamon Briggs, Deputy General Counsel; Shayda Bakhshi, Outreach Coordinator; and Lily Moreno, Executive Assistant.

#### **A. Announcements**

President Spier made general announcements, including concerning continuing education credit for attending the Board Meeting, and reviewed the meeting procedures.

#### **B. Discussion and Approval of Minutes of Previous Meetings (Item B)**

Following discussion, the motion was made by Mr. Tisch to approve the minutes of the Board Business Meeting held February 6, 2024. The motion was seconded by Mr. Lewis and passed unanimously.

---

<sup>1</sup>See agenda and corresponding attachments for supporting materials.

**C. Discussion of and Possible Action Regarding Rules**

Final Adoption of Rules

- Rules Concerning Delivery of Prescription Drugs (§291.12) (Item C.1.1)

Mr. Griffith explained that the Board voted to propose new rule §291.12 during its February 6, 2024, meeting. The proposed rule was published in the March 22, 2024, issue of the *Texas Register*.

Mr. Griffith directed the Board's attention to §291.12 and explained that the new rule specifies requirements for the delivery of prescription drugs to a patient or patient's agent. He also explained that a revised version had been prepared by Board staff.

Written comments were received from the following:

- Doug Read, Pharm.D., R.Ph., President, Texas Federation of Drug Stores, with suggested changes to the proposed rule;
- Jeenu Philip, R.Ph., Director, Pharmacy Affairs, Walgreen Co., with suggested changes to the proposed rule;
- Lauren Paul, Pharm.D., Executive Director, Pharmacy Regulatory Affairs, CVS Health, expressing concern and with suggested changes to the proposed rule;
- Anne Titus Hilby, Deputy General Counsel, Zipline International Inc., in support of the proposed rule;
- Johnny Garcia, Pharm.D., R.Ph., Senior Director, Policy, Pharmaceutical Care Management Association, expressing concern and with suggested changes to the proposed rule;
- A.J. Day, Pharm.D., Vice President, Clinical Services, PCCA, with suggested clarification and grammatical corrections to the proposed rule; and
- Halister Joseph Drummond, Pharm.D., R.Ph., Pharmacist-in-Charge, Austin Compounding Pharmacy, in support of the proposed rule, with suggested changes.

Oral comments were received from the following:

- Jason Davis, R.Ph., Vice President, Texas Pharmacy Association, in support of the proposed rule; and
- Mr. Philip, reiterating his written comments; and
- Ms. Paul, reiterating her written comments.

Following discussion and review of the Preamble and Order Adopting Rules, a motion was made by Mr. Fernandez to approve for adoption, by Board Order, new rule §291.12, as revised, and striking Line 154. The motion was seconded by Mr. Marquis and failed 3-7-0, with Mr. Lewis, Mr. Martin, Mr. Miller, Ms. Montemayor, Mr. Shaw, Ms. Tijerina, and

Ms. Yoakum opposed. The motion was made by Mr. Lewis to approve for adoption, by Board Order, new rule §291.12, as revised, and adding that patient complaints may be included in the patient profile to Line 154. The motion was seconded by Ms. Yoakum and passed 7-3-0, with Mr. Fernandez, Mr. Marquis, and Mr. Tisch opposed.

- Rules Concerning Pharmacies Compounding Non-Sterile Preparations (§291.131) (Item C.1.2)

Mr. Griffith explained that the Board voted to propose the amendments to §291.131 during its February 6, 2024, meeting. The proposed amendments were published in the March 22, 2024, issue of the *Texas Register*.

Mr. Griffith directed the Board's attention to amendments to §291.131 and explained that the amendments update the personnel, environment, labeling, compounding process, quality assurance, and recordkeeping requirements for pharmacies compounding non-sterile preparations.

Written comments were received from:

- Mr. Day, with suggested changes to the proposed rule; and
- Mr. Drummond, in support of the proposed amendments, with suggested changes.

Oral comments were received from:

- Mr. Day, reiterating his written comments; and
- Mr. Davis, in support of the proposed amendments.

Mr. Marquis left the meeting at 10:44 a.m.

Following discussion and review of the Preamble and Order Adopting Rules, the motion was made by Ms. Yoakum to approve for adoption, by Board Order, the amendments to §291.131, as presented and with the modifications set forth in the discussion. The motion was seconded by Mr. Lewis and passed unanimously.

President Spier recessed the meeting at 10:54 a.m.

Mr. Tisch left the meeting during the break.

President Spier reconvened the meeting at 11:13 a.m.

**D. Discussion of and Possible Action Concerning Pilot Projects**

- Report on Pilot Project Concerning Residential Delivery of Prescription Drugs by Means of Drone Delivery Service (D.1)

President Spier directed the Board's attention to a report from Amazon Pharmacy regarding the pilot project concerning residential delivery of prescription drugs by means of drone delivery service.

President Spier recognized Ehihimen Okogbo, R.Ph., Pharmacist-in-Charge of Amazon Pharmacy #008; and Sean Baird, Senior Corporate Counsel, Amazon Legal, who reviewed the report and answered questions from the Board concerning the pilot project.

**C. Discussion of and Possible Action Regarding Rules, continued**

Proposal of Rules

- Rules Concerning Automatic Denial or Revocation (§281.69) (Item C.2.1)

Mr. Griffith directed the Board's attention to suggested amendments to rule language concerning automatic denial or revocation. He explained the proposed amendments to §281.69 correct subparagraph lettering and grammatical errors.

Following discussion, the motion was made by Mr. Miller to approve for proposal amendments to §281.69, as presented. The motion was seconded by Mr. Martin and passed unanimously.

Rule Review

Mr. Griffith directed the Board's attention to the Board Review Plan for FY2022-FY2025 (Item C.3).

- For Adoption
  - Chapter 281 Concerning Administrative Practices and Procedures (§§281.1 – 281.23, 281.30 – 281.35, 281.60 – 281.70) (Item C.3.1.1)
  - Chapter 311 Concerning Code of Conduct (§§311.1 – 311.2) (Item C.3.1.2)
  - Chapter 291 Concerning Pharmacies (All Classes of Pharmacies) (§§291.1 – 291.11, 291.14 – 291.19, 291.22 – 291.23, 291.27 – 291.29) (Item C.3.1.3)

- Chapter 291 Concerning Pharmacies (Clinic Pharmacy (Class D)) (§§291.91 – 291.94) (Item C.3.1.4)
- Chapter 291 Concerning Pharmacies (Non-Resident Pharmacy (Class E)) (§§291.101 – 291.106) (Item C.3.1.5)
- Chapter 295 Concerning Pharmacists (§§295.1 – 295.9, 295.11 – 295.16) (Item C.3.1.6)

Following discussion, in accordance with Government Code §2001.039, the motion was made by Ms. Montemayor to approve for adoption, as presented, the review of Chapter 281 Concerning Administrative Practices and Procedures (§§281.1 – 281.23, 281.30 – 281.35, 281.60 – 281.70), Chapter 311 Concerning Code of Conduct (§§311.1 – 311.2), Chapter 291 Concerning Pharmacies (All Classes of Pharmacies) (§§291.1 – 291.11, 291.14 – 291.19, 291.22 – 291.23, 291.27 – 291.29), Chapter 291 Concerning Pharmacies (Clinic Pharmacy (Class D)) (§§291.91 – 291.94), Chapter 291 Concerning Pharmacies (Non-Resident Pharmacy (Class E)) (§§291.101 – 291.106), Chapter 295 Concerning Pharmacists (§§295.1 – 295.9, 295.11 – 295.16). The motion was seconded by Ms. Tijerina and passed unanimously.

- For Proposal
  - Chapter 291 Concerning Pharmacies (Institutional Pharmacy (Class C)) (§§291.71 – 291.77) (Item C.3.2.1)
  - Chapter 303 Concerning Destruction of Dangerous Drugs & Controlled Substances (§§303.1 – 303.3) (Item C.3.2.2)

Following discussion, in accordance with Government Code §2001.039, the motion was made by Mr. Lewis to approve for proposal, as presented, the review of Chapter 291 Concerning Pharmacies (Institutional Pharmacy (Class C)) (§§291.71 – 291.77) and Chapter 303 Concerning Destruction of Dangerous Drugs & Controlled Substances (§§303.1 – 303.3). The motion was seconded by Mr. Martin and passed unanimously.

**F. Discussion of and Possible Action Concerning the Following Reports and Discussions**

- Discussion on §291.133 Concerning Pharmacies Compounding Sterile Preparations and USP 797 (Item F.10)

Ms. Holloway directed the Board's attention to a chart prepared by Board staff indicating the changes to §291.133 recommended by the Compounding Rules Advisory Group sterile subcommittee in consideration of USP 797 revisions. She explained that the Board previously reviewed the chart at the February 6, 2024, meeting, and directed Board staff to

draft rules. Ms. Holloway explained that to move forward with rule drafting decisions were needed concerning the areas where the sterile subcommittee members were unable to come to a consensus. Ms. Holloway reviewed each of the areas of disagreement, which included viable air sampling frequency, maximum batch size, beyond-use-dating for Category 2, and beyond-use-dating for Category 3.

Mr. Marquis rejoined the meeting at 11:35 a.m.

President Spier recognized members of the sterile subcommittee, Daniel Nyakundi, Ph.T.R.; Jim Hrcir, R.Ph.; and Jasper Lovoi, Pharm.D., R.Ph., who explained their recommendations concerning the items of disagreement. The Board also heard a recorded video comment from subcommittee member Cole Knutson, R.Ph.

President Spier opened discussion concerning the items of disagreement.

In response to a request by Ms. Yoakum to allow comments from an audience member to assist with the discussion, President Spier suggested recessing and continuing discussion after the break and scheduled agenda items.

President Spier recessed the meeting at 12:41 p.m.

Mr. Marquis left the meeting during the break.

President Spier reconvened the meeting at 1:15 p.m.

## **H. Disciplinary Orders**

- Consideration of Proposal for Decision in the Matter of Pearl Odinka Anusim, Pharmacist License #32584 (Item H.1)

Ms. Murphy directed the Board's attention to the Proposal for Decision and the corresponding proposed Board Order options. She advised the Board that following a hearing held before an Administrative Law Judge (ALJ) with the State Office of Administrative Hearings, a Proposal for Decision was issued on January 12, 2024, in the matter of Pearl Odinka Anusim. Ms. Murphy reviewed the background in the case for the Board. She explained that on January 25, 2024, Board staff filed written exceptions to the proposal for decision, which alerted the ALJ to a mischaracterization of staff testimony and an incorrectly stated finding of fact. On February 14, 2024, the ALJ granted the request for exceptions and recommended that Ms. Anusim's license be reprimanded. Ms. Murphy directed the Board's attention to two options for Board Order #2023-02091, one with recommendations from the ALJ, which would

reprimand Ms. Anusim's license, and the other with Board staff's recommendations, which would impose an administrative penalty of \$2,000, consistent with precedent, the schedule of administrative penalties in §286.51, and the recommendation of the informal conference panel.

Mr. Marquis rejoined the meeting at 1:18 p.m.

President Spier recognized Ms. Anusim, who explained her position.

Following discussion, the motion was made by Mr. Shaw to accept the Findings of Fact and Conclusions of Law in the Proposal for Decision and to approve the entry of Board Order #2023-02091, as recommended by Board staff, in the matter of Pearl Odinaka Anusim. The motion was seconded by Mr. Lewis and passed 8-1-0, with Mr. Marquis opposed.

**F. Discussion of and Possible Action Concerning the Following Reports and Discussions, continued**

- Review and Approval of FY2024 Annual Internal Audit Report (Item F.4)

President Spier recognized Daniel Graves, Weaver and Tidwell, LLP, who reviewed the status of the FY2024 Annual Internal Audit. He indicated that follow-ups were in process and would be presented at the Board's next meeting.

President Spier announced that the Board would go into Executive Session for the purpose of conducting deliberations regarding security devices or security audits under the authority of the Texas Government Code, Sections 551.076 and 551.089.

President Spier declared the Board in Executive Session at 1:39 p.m.

At 1:52 p.m., President Spier announced that the Board would resume the meeting in Open Session and that no action was taken and no decisions were made during Executive Session.

President Spier explained that because the completed report was not available, the Board would review the completed report for approval at the next meeting.

- Discussion on §291.133 Concerning Pharmacies Compounding Sterile Preparations and USP 797 (Item F.10), continued

President Spier recognized Mr. Day, who indicated that he had attended several of the USP meetings and the compounding conference hosted by USP. Mr. Day provided background concerning the USP recommendation

on maximum batch size.

Following discussion, the Board recommended drafting the amendments to §291.133 using an air sampling frequency of at least every 3 months for Category 3, a maximum batch size of 500 final yield units, the longer beyond-use-dating for Category 2, and the USP recommended dating for Category 3.

- Professional Recovery Network
  - Ms. Hotchkiss discussed performance measures regarding the number of individuals participating in the peer assistance program for the second quarter of FY2024 (December 1, 2023 – February 29, 2024). (Item F.3.1)
  - President Spier recognized PRN Program Director Raquel Leal, LPC. Ms. Leal directed the Board's attention to the PRN expense report for the second quarter of FY2024 (December 1, 2023 – February 29, 2024) and reviewed PRN activities for the Board. (Item F.3.2)

**E. Discussion of and Possible Action Concerning Reports of Committees/ Task Forces**

- Report on Prescription Monitoring Program (PMP) Advisory Committee (Item E.1)

Mr. Meryman provided a reminder that there is still a vacancy on the PMP Advisory Committee for a physician that performs surgery. He reported that the advisory committee meeting was held on March 28, 2024, and included presentations from Bamboo Health and UT Center for Health Communication. Mr. Meryman also reported that the advisory committee chose to continue meeting quarterly and the next meeting is scheduled for June 27, 2024.

- Report on Interagency Prescription Monitoring Program Work Group (Item E.3)

Dr. Carroll reported that the Interagency Prescription Monitoring Program Workgroup Meeting had not met since the previous Board meeting, and the next meeting had not yet been scheduled.



**F. Discussion of and Possible Action Concerning the Following Reports and Discussions, continued**

- Financial Report
  - Review of FY2024 Second Quarter Expenditures (Item F.1.1)

Mr. Leal reviewed the expenditures for the second quarter of FY2024 (December 1, 2023 – February 29, 2024) for the Board.
  - Review of Board Member Travel Budget (Item F.1.2)

Mr. Leal reviewed the Board Member Travel Budget for the second quarter of FY2024 (December 1, 2023 – February 29, 2024).
  - Consideration of Material Changes to Contracts for Goods and Services Awarded Under Chapter 2155 of Texas Government Code (Item F.1.3)

Mr. Leal reported that there were no material changes to contracts for goods and services for the second quarter of FY2024 (December 1, 2023 – February 29, 2024).
  - Review and Approval of Legislative Appropriations Request for FY2026-2027 (includes exceptional items and fee projections) (Item F.1.4)

President Spier reported that the Board Executive Committee met on May 2, 2024, and approved the Legislative Appropriations Request for review by the Board.

Ms. Driscoll directed the Board's attention to the Proposed Exceptional Items for the FY2026-2027 Legislative Appropriations Request. She reviewed each of the proposed exceptional items and the potential fee increases if all items are approved.

Following review and discussion, the motion was made by Mr. Martin to approve the Proposed Exceptional Items for FY2026-2027 for the Legislative Appropriations Request, as presented, and allowing for Dr. Carroll in consultation with the Board president to make adjustments for any additional circumstances that might arise. The motion was seconded by Mr. Lewis and passed unanimously.
- Review and Approval of FY2025-FY2029 Strategic Plan and Customer Service Survey (Item F.2)

Dr. Carroll directed the Board's attention to a draft of the FY2025-FY2029

Strategic Plan, which includes the Customer Service Survey.

Following review, a motion was made by Mr. Martin to approve the FY2025-FY2029 Strategic Plan, as presented. The motion was seconded by Mr. Shaw and passed unanimously.

- Review of FY2025 Calendar of Events (Item F.5)

President Spier reviewed the FY2025 Calendar of Events (September 1, 2024 – August 31, 2025) for the Board.

- Report on Prescription Monitoring Program (Item F.6)

Mr. Meryman reviewed the Prescription Monitoring Program (PMP) data for the second quarter of FY2024 (December 1, 2023 – February 29, 2024). Mr. Meryman also reported on PMP feature updates and PMP staffing updates.

- Report on Appeals from State Office of Administrative Hearing Cases and Other Court Actions (Item F.7)

Ms. Holloway reported that there have been no updates since the last meeting concerning the lawsuit filed by Lightcare Rx, LLC (Texas Pharmacy License #32609) and the pharmacist-in-charge, Leila Elahianboroujeni (Pharmacist License #64241), in the Travis County District Court, appealing the entry of the Board Orders entered in May 2022.

- Discussion Concerning National Association of Boards of Pharmacy (NABP) Proposed Resolutions (Item F.8)

President Spier explained that the Board had received a copy of the National Association of Boards of Pharmacy (NABP) proposed resolutions. She reviewed each proposed resolution with the Board for feedback on how to vote as the delegate at the upcoming NABP Annual Meeting.

Mr. Shaw left the meeting at 3:01 p.m.

#### **G. Consideration of and Possible Action Concerning Enforcement Reports**

- Report on Complaints Closed and Dismissed During the Previous Quarter (Item G.1)

Ms. Hotchkiss reported on complaints dismissed and closed during the second quarter of FY2024 (December 1, 2023 – February 29, 2024). The

report also included a comparison of complaints closed with disciplinary orders to those closed without disciplinary orders and a comparison of quarterly averages for FY2024 to the quarterly averages for FY2023, as well as percentage change from FY2023 to FY2024.

- Report on Status of Active/Pending Complaints (Item G.2)

Ms. Hotchkiss reviewed the *Report on Status of Active/Pending Complaints* for the Board.

#### H. **Disciplinary Orders, continued**

- Report on Agreed Board Orders and Board Orders Entered by Executive Director (Item H.2)
  - The Board reviewed 14 Agreed Board Orders concerning pharmacy technicians and pharmacy technician trainees that had been entered by the Executive Director on behalf of the Board, in accordance with the Board's directives, during the period from February 12, 2024, through April 15, 2024.
  - The Board reviewed 5 Agreed Board Orders concerning pharmacies and pharmacists that had been entered by the Executive Director on behalf of the Board, in accordance with the Board's directives, during the period from February 28, 2024, through April 15, 2024.
  - The Board reviewed 10 Board Orders concerning pharmacies that had been entered by the Executive Director on behalf of the Board, in accordance with the Board's directives, during the period from February 16, 2024, through April 30, 2024.
  - The Board reviewed 1 Confidential Agreed Board Order concerning a pharmacist that had been entered by the Executive Director on behalf of the Board, in accordance with the Board's directives, on April 1, 2024.
- Discussion of and Action on Proposed Agreed Board Orders, Proposed Default Board Orders, and Proposed Remedial Plans (Items H.3 and H.4)

The Board reviewed the alleged violations, as well as the recommended sanctions for each of the following:

- 21 proposed Agreed Board Orders concerning pharmacy technicians and pharmacy technician trainees who appeared for an Informal Conference;

- 5 proposed Default Board Orders concerning pharmacy technicians and pharmacy technician trainees who did not appear for an Informal Conference;
- 30 proposed Agreed Board Orders concerning pharmacies and pharmacists (Alternative Resolutions);
- 24 proposed Agreed Board Orders concerning pharmacies, pharmacists, and interns who appeared for an Informal Conference;
- 1 proposed Default Board Orders concerning a pharmacist (Following a State Office of Administrative Hearing);
- 1 proposed Confidential Agreed Board Order concerning a pharmacist (Alternative Resolutions);
- 1 proposed Confidential Agreed Board Order concerning a pharmacist who appeared for an Informal Conference;
- 4 proposed Remedial Plans concerning pharmacies and pharmacists (Alternative Resolutions); and
- 7 proposed Remedial Plans concerning pharmacists and interns who attended an Informal Conference.

The motion was made by Mr. Lewis to approve the proposed Disciplinary Orders and Remedial Plans, as presented. The motion was seconded by Ms. Yoakum, and the motion passed as follows:

No.	Name	T, I, R, or P*	ABO, DBO, or RP**	Order # or Plan #	Board Vote (Yes-No-Abstain)	Abstained Board Members
1	Elijah Larenz Gallegos	T	ABO	2024-01853	8-0-0	-
2	Waleska Citlaly Baka	T	ABO	2022-06376	7-0-1	Fernandez
3	Michele Trudy Noel	T	ABO	2023-02914	6-0-2	Miller, Montemayor
4	Patrick Ryan Wood	T	ABO	2023-03556	6-0-2	Miller, Montemayor
5	Mathaba Ahmed	T	ABO	2023-06778	7-0-1	Yoakum
6	Brandi Dawn Criswell	T	ABO	2024-00236	7-0-1	Yoakum
7	Hilda N. Gamez	T	ABO	2024-01854	7-0-1	Yoakum
8	Elida Marie Holbrook	T	ABO	2022-07374	7-0-1	Yoakum
9	Christina Williams	T	ABO	2024-00578	7-0-1	Yoakum
10	Manisha Harikrishna Jadav	T	ABO	2023-04735	6-0-2	Fernandez, Lewis
11	Randall Alan Johnson	T	ABO	2024-00320	6-0-2	Fernandez, Lewis
12	Boyd Newman Matthews	T	ABO	2023-05470	6-0-2	Fernandez, Lewis

\*Technician or Technician Trainee (T), Pharmacist Intern (I), Pharmacist (R), and Pharmacy (P)

\*\*Agreed Board Order (ABO), Default Board Order (DBO), and Remedial Plan (RP)

TSBP Board Business Meeting

Minutes/May 7, 2024

Page 13

No.	Name	T, I, R, or P*	ABO, DBO, or RP**	Order # or Plan #	Board Vote (Yes-No-Abstain)	Abstained Board Members
13	Jacqueline Monique Nicholson	T	ABO	2024-01071	6-0-2	Fernandez, Lewis
14	Karen Ting-Fun Shiue	T	ABO	2023-05746	6-0-2	Fernandez, Lewis
15	Ladora Basaldu	T	ABO	2024-01504	6-0-2	Montemayor, Yoakum
16	Nurrudin Daredia	T	ABO	2024-01503	6-0-2	Montemayor, Yoakum
17	Vanessa Yvonne Hernandez	T	ABO	2024-03269	7-0-1	Montemayor
18	Youssef Kaba	T	ABO	2024-00295	6-0-2	Montemayor, Yoakum
19	Eric Lopez	T	ABO	2024-03328	6-0-2	Montemayor, Yoakum
20	Ashleigh Lillian Moore	T	ABO	2023-03460	6-0-2	Montemayor, Yoakum
21	Remmassive Latuna Selmon	T	ABO	2024-01603	6-0-2	Montemayor, Yoakum
22	Wesley Aaron Griffin	T	DBO	2023-04295	6-0-2	Fernandez, Lewis
23	Angelica Emily Gutierrez	T	DBO	2023-05800	6-0-2	Fernandez, Lewis
24	Adham Abdelrahman	T	DBO	2023-06184	6-0-2	Montemayor, Yoakum
25	Hilda N. Gamez	T	DBO	2024-02400	6-0-2	Montemayor, Yoakum
26	Adonis Francisco Vasquez	T	DBO	2024-02710	6-0-2	Montemayor, Yoakum
27	Best Value Renshaw Drug	P	ABO	2024-00854	8-0-0	-
28	CVS/pharmacy #1108	P	ABO	2023-03530	7-0-1	Tijerina
29	Phyllis Booker Thomas	R	ABO	2024-00688	7-0-1	Tijerina
30	CVS/pharmacy #2996	P	ABO	2024-02149	7-0-1	Tijerina
31	CVS/pharmacy #6850	P	ABO	2024-01228	7-0-1	Tijerina
32	CVS/pharmacy #7827	P	ABO	2023-07256	7-0-1	Tijerina
33	CVS/pharmacy #10637	P	ABO	2023-06294	7-0-1	Tijerina
34	CVS/pharmacy #16847	P	ABO	2023-06759	7-0-1	Tijerina
35	Jan Staab	R	ABO	2024-03213	7-0-1	Tijerina
36	Linda Van Ratliff Davis	R	ABO	2024-00535	8-0-0	-
37	Gibson Discount Pharmacy	P	ABO	2023-06901	8-0-0	-
38	Sheryne Elise McClure	R	ABO	2024-00909	8-0-0	-
39	Harding & Parker Pharmacy	P	ABO	2023-05467	8-0-0	-
40	H.E.B. Pharmacy #070	P	ABO	2023-03094	7-0-1	Montemayor
41	H.E.B. Pharmacy #099	P	ABO	2023-06336	7-0-1	Montemayor
42	H.E.B. Pharmacy #737	P	ABO	2023-05031	7-0-1	Montemayor
43	Hero Home Delivery & Specialty Pharmacy	P	ABO	2023-05995	8-0-0	-

\*Technician or Technician Trainee (T), Pharmacist Intern (I), Pharmacist (R), and Pharmacy (P)

\*\*Agreed Board Order (ABO), Default Board Order (DBO), and Remedial Plan (RP)

TSBP Board Business Meeting

Minutes/May 7, 2024

Page 14

No.	Name	T, I, R, or P*	ABO, DBO, or RP**	Order # or Plan #	Board Vote (Yes- No- Abstain)	Abstained Board Members
44	Jordan G. Baluyot	R	ABO	2023-06383	8-0-0	-
45	Fidelia-Codelia O. Meremikwu	R	ABO	2024-01612	8-0-0	-
46	Elissa Meyer	R	ABO	2023-06384	8-0-0	-
47	NB Pharmacy	P	ABO	2023-05946	8-0-0	-
48	Sonder Pharmacy LLC	P	ABO	2023-03624	8-0-0	-
49	Thrive Rx	P	ABO	2024-00453	8-0-0	-
50	United Pharmacy #532	P	ABO	2023-03531	8-0-0	-
51	Bradley Scott Robinson	R	ABO	2024-01962	8-0-0	-
52	Walgreens #09946	P	ABO	2024-00511	7-0-1	Fernandez
53	Walgreens #12292	P	ABO	2023-03518	7-0-1	Fernandez
54	Walmart Pharmacy 10-464	P	ABO	2023-07331	8-0-0	-
55	Walmart Pharmacy 10-572	P	ABO	2023-07099	8-0-0	-
56	Sammy Redden	R	ABO	2024-01432	8-0-0	-
57	Samples Rx Pharmacy	P	ABO	2023-03037	6-0-2	Miller, Tijerina
58	Procure Pharmaceutical Services	P	ABO	2023-05045	6-0-2	Miller, Montemayor
59	Brown Bag Pharmacy	P	ABO	2023-05103	6-0-2	Fernandez, Yoakum
60	Christian Family Pharmacy	P	ABO	2023-03821	6-0-2	Fernandez, Yoakum
61	Health-Rite Pharmacy	P	ABO	2023-03632	6-0-2	Fernandez, Yoakum
62	Gerald Christopher Melvin	R	ABO	2023-03822	6-0-2	Fernandez, Yoakum
63	Aderonke Akanke Adesokan	R	ABO	2023-05114	7-0-1	Yoakum
64	Apothecary Shoppe	P	ABO	2023-02036	7-0-1	Yoakum
65	Sabrina Kaye Griggs	R	ABO	2023-04871	7-0-1	Yoakum
66	Corey James Todd	R	ABO	2023-03056	7-0-1	Yoakum
67	Kingsley Onimisi Jademi	R	ABO	2023-02957	7-0-1	Yoakum
68	Shantae Yvette Shepard	R	ABO	2023-02957	7-0-1	Yoakum
69	Saladdin Yousef Mohammed Abu Sada	R	ABO	2023-04731	6-0-2	Fernandez, Lewis
70	Folorunso Oluremi Akinyele	R	ABO	2023-06882	7-0-1	Fernandez
71	Stephanie Anne Caffey	R	ABO	2023-06286	6-0-2	Fernandez, Lewis
72	H.E.B. Pharmacy #498	P	ABO	2023-01158	5-0-3	Fernandez, Lewis, Montemayor
73	Charles Jude Mitchell	R	ABO	2024-00268	6-0-2	Fernandez, Lewis
74	Shiva Peddireddy	R	ABO	2024-00398	6-0-2	Fernandez, Lewis
75	Rx Plus Pharmacy of Live Oak	P	ABO	2024-00131	6-0-2	Fernandez, Lewis
76	Carolina Canales	R	ABO	2024-00751	6-0-2	Fernandez, Lewis

\*Technician or Technician Trainee (T), Pharmacist Intern (I), Pharmacist (R), and Pharmacy (P)

\*\*Agreed Board Order (ABO), Default Board Order (DBO), and Remedial Plan (RP)

No.	Name	T, I, R, or P*	ABO, DBO, or RP**	Order # or Plan #	Board Vote (Yes- No- Abstain)	Abstained Board Members
77	Himanshu Bhagavabhai Patel	R	ABO	2024-00752	6-0-2	Fernandez, Lewis
78	Brookshire Brothers Pharmacy #9	P	ABO	2023-05503	6-0-2	Montemayor, Yoakum
79	Charles Thomas Lhota	I	ABO	2024-02228	6-0-2	Montemayor, Yoakum
80	Stonegate Pharmacy	P	ABO	2024-01431	6-0-2	Montemayor, Yoakum
81	Pearl Odinaka Anusim	R	DBO	2023-02091	7-0-1	Tijerina
82	<i>Confidential</i>	R	ABO	2023-06630	8-0-0	-
83	<i>Confidential</i>	R	ABO	2024-02758	6-0-2	Montemayor, Yoakum
84	Donna Marie Herbert	R	RP	2024-01394	8-0-0	-
85	Thanh Kien Ho	R	RP	2024-01821	8-0-0	-
86	One Source Specialty Medicine	P	RP	2024-00414	8-0-0	-
87	Stephen Thomas	R	RP	2024-00415	8-0-0	-
88	Afroz Ahmed	R	RP	2023-05322	6-0-2	Fernandez, Yoakum
89	Mine Chinaka Amala	R	RP	2023-05323	6-0-2	Fernandez, Yoakum
90	Ijeoma Maduka	R	RP	2023-05382	6-0-2	Lewis, Yoakum
91	Konstantin Victorovich Gawlik	R	RP	2023-04325	6-0-2	Fernandez, Lewis
92	Ugochukwu Kingsley Mozie	I	RP	2023-06926	6-0-2	Fernandez, Lewis
93	Freeman Thomas Wyche II	R	RP	2024-00702	6-0-2	Fernandez, Lewis
94	Helen Xi Chen	R	RP	2023-05484	6-0-2	Montemayor, Yoakum

\*Technician or Technician Trainee (T), Pharmacist Intern (I), Pharmacist (R), and Pharmacy (P)

\*\*Agreed Board Order (ABO), Default Board Order (DBO), and Remedial Plan (RP)

## I. Miscellaneous

- Items to be Placed on Agenda for August 6, 2024, Board Meeting (Item I.1)

President Spier requested Board members to submit any additional items for the August 6, 2024, Board meeting to staff.

- Discussion of and Possible Action on Upcoming Meetings (Item I.2)

President Spier reviewed plans for the upcoming NABP meeting. She also reviewed upcoming informal conferences.

Mr. Marquis left the meeting at 3:19 p.m.

**J. Consideration of Personnel Matters**

- Executive Session to Conduct Evaluation of Executive Director (Item J.1)

President Spier announced that the Board go into Executive Session to consider personnel matters under the authority of the Texas Government Code, §551.074.

President Spier declared the Board in Executive Session at 3:22 p.m.

At 3:45 p.m., President Spier announced that the Board would resume the meeting in Open Session and that no action was taken and no decisions were made during Executive Session.


Mr. Martin made a motion to adjourn the meeting. The motion was seconded by Ms. Montemayor and passed unanimously.

President Spier adjourned the meeting at 3:46 p.m.

APPROVED:



Julie Spier, R.Ph.  
President



Daniel Carroll, Pharm.D., R.Ph.  
Executive Director/Secretary

August 6, 2024